My Watchlist Items

      No Watchlist
Array ( [0] => stdClass Object ( [symbol] => GLTO [price] => 5.61 [beta] => 0 [volAvg] => 460404 [mktCap] => 141718704 [lastDiv] => 0 [range] => 4.502-17.99 [changes] => -2.39 [companyName] => Galecto, Inc. [currency] => USD [cik] => 0001800315 [isin] => [cusip] => [exchange] => NMS [exchangeShortName] => NASDAQ [industry] => Biotechnology [website] => http://galecto.com [description] => Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung. Its products also comprise GB2064, which is in Phase I/IIa for the treatment of myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase I/IIa for the treatment of fibrosis related to non-alcoholic steatohepatitis, as well as development of other related indications, including cancer. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark. [ceo] => Dr. Hans T. Schambye [sector] => Healthcare [country] => DK [fullTimeEmployees] => 28 [phone] => 45 70 70 52 10 [address] => Ole Maaloes Vej 3 [city] => Copenhagen [state] => [zip] => [dcfDiff] => [dcf] => 0 [image] => https://financialmodelingprep.com/image-stock/GLTO.png [ipoDate] => 2020-10-29 [defaultImage] => [isEtf] => [isActivelyTrading] => 1 ) )
Galecto, Inc. (GLTO)
   5.61   -2.39(-29.88%)
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung. Its products also comprise GB2064, which is in Phase I/IIa for the treatment of myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase I/IIa for the treatment of fibrosis related to non-alcoholic steatohepatitis, as well as development of other related indications, including cancer. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.
TitleNamePayCurrency PayGenderYear BornTitle Since
Chief Medical Officer Prof. Bertil Lindmark M.D., Ph.D. N/A USD N/A N/A
Chief Financial Officer Mr. Jonathan P. Freve CPA, CPA N/A USD male N/A N/A
Co-Founder & Member of the Clinical Advisory Board - IPF Prof. Tariq Sethi M.D., B.Sc., M.A., Ph.D., FRCP N/A USD N/A N/A
Co-Founder Dr. Hakon Leffler N/A USD N/A N/A
Co-Founder Mr. Ulf J. Nilsson N/A USD male N/A N/A
Chief Operating Officer Mr. Anders Pedersen 355000 USD male 1960 N/A
Co-Founder, Pres & Chief Executive Officer Dr. Hans T. Schambye 479000 USD 1966 N/A
SymbolDateRatingRating Score Rating Details
GLTO 11 June, 2021 A- 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Strong Buy)
GLTO 10 June, 2021 A- 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Strong Buy)
GLTO 9 June, 2021 A- 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Strong Buy)
GLTO 8 June, 2021 A- 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Strong Buy)
GLTO 7 June, 2021 A- 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Strong Buy)
GLTO 4 June, 2021 A- 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Strong Buy)
GLTO 3 June, 2021 A- 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Strong Buy)
GLTO 2 June, 2021 A- 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Strong Buy)
GLTO 1 June, 2021 A- 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Strong Buy)
GLTO 28 May, 2021 A- 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Strong Buy)
GLTO 27 May, 2021 A- 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Strong Buy)
GLTO 26 May, 2021 A- 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Strong Buy)
GLTO 25 May, 2021 A- 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Strong Buy)
GLTO 24 May, 2021 A- 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Strong Buy)
GLTO 21 May, 2021 A- 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Strong Buy)
GLTO 20 May, 2021 A- 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Strong Buy)
GLTO 19 May, 2021 A- 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Strong Buy)
GLTO 18 May, 2021 A- 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Strong Buy)
GLTO 17 May, 2021 A- 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Strong Buy)
GLTO 14 May, 2021 A- 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Strong Buy)
GLTO 13 May, 2021 A- 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Strong Buy)
GLTO 12 May, 2021 A- 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Strong Buy)
GLTO 11 May, 2021 A- 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Strong Buy)
GLTO 10 May, 2021 A- 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Strong Buy)
GLTO 7 May, 2021 A- 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Strong Buy)
GLTO 6 May, 2021 B 3 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Neutral)
GLTO 5 May, 2021 B 3 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Neutral)
GLTO 4 May, 2021 B 3 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Neutral)
GLTO 3 May, 2021 B+ 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Buy)
GLTO 30 April, 2021 B+ 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Buy)
GLTO 29 April, 2021 B+ 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Buy)
GLTO 28 April, 2021 B+ 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Buy)
GLTO 27 April, 2021 B+ 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Buy)
GLTO 26 April, 2021 B+ 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Buy)
GLTO 23 April, 2021 B+ 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Buy)
GLTO 22 April, 2021 B+ 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Buy)
GLTO 21 April, 2021 B+ 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Buy)
GLTO 20 April, 2021 B+ 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Buy)
GLTO 19 April, 2021 B+ 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Buy)
GLTO 16 April, 2021 B+ 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Buy)
GLTO 15 April, 2021 B+ 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Buy)
GLTO 14 April, 2021 B+ 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Buy)
GLTO 13 April, 2021 B+ 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Buy)
GLTO 12 April, 2021 B+ 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Buy)
GLTO 9 April, 2021 B+ 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Buy)
GLTO 8 April, 2021 B+ 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Buy)
GLTO 7 April, 2021 B+ 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Buy)
GLTO 6 April, 2021 B+ 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Buy)
GLTO 5 April, 2021 B+ 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Buy)
GLTO 1 April, 2021 B+ 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Buy)
GLTO 31 March, 2021 B 3 Rating DCF: (Strong Buy)
Rating ROE: (Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Buy)
GLTO 30 March, 2021 B 3 Rating DCF: (Strong Buy)
Rating ROE: (Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Buy)
GLTO 29 March, 2021 B 3 Rating DCF: (Strong Buy)
Rating ROE: (Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Buy)
GLTO 26 March, 2021 B 3 Rating DCF: (Strong Buy)
Rating ROE: (Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Sell)
Rating PB: (Buy)
HolderSharesDate ReportedChange
ORBIMED ADVISORS LLC 4090937 31 December, 2020 4090937
NOVO HOLDINGS A/S 2497791 31 December, 2020 2497791
CORMORANT ASSET MANAGEMENT, LP 2150732 31 December, 2020 2150732
JANUS HENDERSON GROUP PLC 1335569 31 December, 2020 1335569
BLACKROCK INC. 654870 31 December, 2020 654870
SOLEUS CAPITAL MANAGEMENT, L.P. 649600 31 December, 2020 649600
MAVERICK CAPITAL LTD 490452 31 December, 2020 490452
SPHERA FUNDS MANAGEMENT LTD. 391787 31 December, 2020 391787
ASYMMETRY CAPITAL MANAGEMENT, L.P. 337352 31 December, 2020 337352
LAURION CAPITAL MANAGEMENT LP 207552 31 December, 2020 207552
FMR LLC 133333 31 December, 2020 133333
MONASHEE INVESTMENT MANAGEMENT LLC 84163 31 December, 2020 84163
MILLENNIUM MANAGEMENT LLC 70011 31 December, 2020 70011
TUDOR INVESTMENT CORP ET AL 64415 31 December, 2020 64415
WEISS MULTI-STRATEGY ADVISERS LLC 41146 31 December, 2020 41146
CAAS CAPITAL MANAGEMENT LP 20000 31 December, 2020 20000
FEDERATED HERMES, INC. 20000 31 December, 2020 20000
BANK OF AMERICA CORP /DE/ 4488 31 December, 2020 4488
MORGAN STANLEY 1000 31 December, 2020 1000
SymbolTransaction DateReporting CikSecurities Owned Company CikReporting NameAcquistion Or DispositionForm Type Securities TransactedSecurity NameLink
GLTO 26 May, 2021 0001110780 18000 0001800315 GOLDFISCHER CARL A 4 18000 Stock Option (right to buy) View
GLTO 26 May, 2021 0001650322 18000 0001800315 Dallas Jayson Donald Alexander A 4 18000 Stock Option (right to buy) View
GLTO 26 May, 2021 0001609405 18000 0001800315 Khuong Chau Quang A 4 18000 Stock Option (right to buy) View
GLTO 26 May, 2021 0001797917 18000 0001800315 Prener Anne A 4 18000 Stock Option (right to buy) View
GLTO 8 January, 2021 0001797917 18000 0001800315 Prener Anne A 4 18000 Stock Option (right to buy) View
GLTO 8 January, 2021 0001797917 6000 0001800315 Prener Anne A 4 6000 Stock Option (right to buy) View
GLTO 5 January, 2021 0001664466 95000 0001800315 Freve Jonathan A 4 95000 Stock Option (right to buy) View
GLTO 5 January, 2021 0001825778 95000 0001800315 Lindmark Bertil A 4 95000 Stock Option (right to buy) View
GLTO 5 January, 2021 0001825776 230000 0001800315 Schambye Hans T. A 4 230000 Stock Option (right to buy) View
GLTO 5 January, 2021 0001825779 100000 0001800315 Pedersen Anders A 4 100000 Stock Option (right to buy) View
GLTO 19 November, 2020 0001650322 18000 0001800315 Dallas Jayson Donald Alexander A 4 18000 Stock Option (right to buy) View
GLTO 19 November, 2020 0001650322 9000 0001800315 Dallas Jayson Donald Alexander A 4 9000 Stock Option (right to buy) View
GLTO 2 November, 2020 0001360578 479470 0001800315 Christgau Stephan A 4 479470 Common Stock View
GLTO 2 November, 2020 0001360578 546136 0001800315 Christgau Stephan A 4 66666 Common Stock View
GLTO 2 November, 2020 0001360578 0 0001800315 Christgau Stephan D 4 184433 Series D Preferred Stock View
GLTO 2 November, 2020 0001609405 2055824 0001800315 Khuong Chau Quang A 4 2055824 Common Shares View
GLTO 2 November, 2020 0001609405 822311 0001800315 Khuong Chau Quang A 4 822311 Common Shares View
GLTO 2 November, 2020 0001609405 191787 0001800315 Khuong Chau Quang A 4 191787 Common Shares View
GLTO 2 November, 2020 0001609405 2579657 0001800315 Khuong Chau Quang A 4 523833 Common Shares View
GLTO 2 November, 2020 0001609405 1031811 0001800315 Khuong Chau Quang A 4 209500 Common Shares View
GLTO 2 November, 2020 0001609405 0 0001800315 Khuong Chau Quang D 4 291999 Series C-2 Preferred Stock View
GLTO 2 November, 2020 0001825776 39928 0001800315 Schambye Hans T. A 4 13931 Common Stock View
GLTO 2 November, 2020 0001825776 0 0001800315 Schambye Hans T. D 4 5359 Series C-1 Preferred Stock View
GLTO 2 November, 2020 0001612551 4793 0001800315 Munshi Amit A 4 4793 Common Stock View
GLTO 2 November, 2020 0001612551 0 0001800315 Munshi Amit D 4 1844 Series D Preferred Stock View
GLTO 2 November, 2020 0001055951 2055824 0001800315 ORBIMED ADVISORS LLC A 4 2055824 Common Shares View
GLTO 2 November, 2020 0001055951 822311 0001800315 ORBIMED ADVISORS LLC A 4 822311 Common Shares View
GLTO 2 November, 2020 0001055951 191787 0001800315 ORBIMED ADVISORS LLC A 4 191787 Common Shares View
GLTO 2 November, 2020 0001055951 2579657 0001800315 ORBIMED ADVISORS LLC A 4 523833 Common Shares View
GLTO 2 November, 2020 0001055951 1031811 0001800315 ORBIMED ADVISORS LLC A 4 209500 Common Shares View
GLTO 2 November, 2020 0001055951 0 0001800315 ORBIMED ADVISORS LLC D 4 291999 Series C-2 Preferred Stock View
GLTO 2 November, 2020 0001825779 3746 0001800315 Pedersen Anders A 4 3746 Common Stock View
GLTO 2 November, 2020 0001825779 0 0001800315 Pedersen Anders D 4 1441 Series C-1 Preferred Stock View
GLTO 2 November, 2020 0001110780 9587 0001800315 GOLDFISCHER CARL A 4 9587 Common Stock View
GLTO 2 November, 2020 0001110780 1020036 0001800315 GOLDFISCHER CARL A 4 1020036 Common Stock View
GLTO 2 November, 2020 0001110780 19432 0001800315 GOLDFISCHER CARL A 4 19432 Common Stock View
GLTO 2 November, 2020 0001110780 0 0001800315 GOLDFISCHER CARL D 4 392367 Series C-3 Preferred Stock View
GLTO 2 November, 2020 0001388325 2164458 0001800315 Novo Holdings A/S A 4 2164458 COMMON STOCK View
GLTO 2 November, 2020 0001388325 2497791 0001800315 Novo Holdings A/S A 4 333333 COMMON STOCK View
GLTO 2 November, 2020 0001388325 0 0001800315 Novo Holdings A/S D 4 25562 SERIES B-1 PREFERRED STOCK View
GLTO 7 October, 2020 0001825776 519940 0001800315 Schambye Hans T. A 4 519940 Stock Option (right to buy) View
GLTO 7 October, 2020 0001825779 77991 0001800315 Pedersen Anders A 4 77991 Stock Option (right to buy) View
GLTO 25 September, 2020 0001609405 148395 0001800315 Khuong Chau Quang D 4 148395 Series D Preferred Stock View
GLTO 25 September, 2020 0001609405 59350 0001800315 Khuong Chau Quang D 4 59350 Series D Preferred Stock View
GLTO 25 September, 2020 0001609405 73773 0001800315 Khuong Chau Quang D 4 73773 Series D Preferred Stock View
GLTO 25 September, 2020 0001612551 1844 0001800315 Munshi Amit A 4 1844 Series D Preferred Stock View
GLTO 25 September, 2020 0001055951 148395 0001800315 ORBIMED ADVISORS LLC D 4 148395 Series D Preferred Stock View
GLTO 25 September, 2020 0001055951 59350 0001800315 ORBIMED ADVISORS LLC D 4 59350 Series D Preferred Stock View
GLTO 25 September, 2020 0001055951 73773 0001800315 ORBIMED ADVISORS LLC D 4 73773 Series D Preferred Stock View
GLTO 25 September, 2020 0001110780 3688 0001800315 GOLDFISCHER CARL A 4 3688 Series D Preferred Stock View
GLTO 24 June, 2020 0001825776 207976 0001800315 Schambye Hans T. A 4 207976 Stock Option (right to buy) View
GLTO 24 June, 2020 0001612551 109187 0001800315 Munshi Amit A 4 109187 Stock Option (right to buy) View
GLTO 24 June, 2020 0001825779 142983 0001800315 Pedersen Anders A 4 142983 Stock Option (right to buy) View
SymbolDatePeriodDownload XLSX File
GLTO 2020 FY Download XLSX File
GLTO 2021 Q1 Download XLSX File
GLTO 2021 Q2 Download XLSX File
GLTO 2020 Q3 Download XLSX File
GLTO 2020 Q4 Download XLSX File

Charts

Company Historical Earnings

DateSymbolEPSEPS EstimatedTimeRevenueRevenue Estimated
4 May, 2021 GLTO bmo 0 0
29 March, 2021 GLTO bmo 0 0

Company Profile

Company Name Galecto, Inc.
Symbol GLTO
Currency USD
Price 5.61
Exchange Name NMS (NASDAQ)
Industry Biotechnology
CEO Dr. Hans T. Schambye
Sector Healthcare
Country DK
Full Time Employees 28
Phone 45 70 70 52 10
Address Ole Maaloes Vej 3
City Copenhagen
>